NO20073632L - Behandling av hepatitt C med interferon-beta i en asiatisk populasjon - Google Patents

Behandling av hepatitt C med interferon-beta i en asiatisk populasjon

Info

Publication number
NO20073632L
NO20073632L NO20073632A NO20073632A NO20073632L NO 20073632 L NO20073632 L NO 20073632L NO 20073632 A NO20073632 A NO 20073632A NO 20073632 A NO20073632 A NO 20073632A NO 20073632 L NO20073632 L NO 20073632L
Authority
NO
Norway
Prior art keywords
treatment
beta
interferon
hepatitis
asian population
Prior art date
Application number
NO20073632A
Other languages
English (en)
Norwegian (no)
Inventor
Theodor Wee Tit Gin
Ian Parsons
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of NO20073632L publication Critical patent/NO20073632L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20073632A 2004-12-16 2007-07-13 Behandling av hepatitt C med interferon-beta i en asiatisk populasjon NO20073632L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04106652 2004-12-16
US63787404P 2004-12-20 2004-12-20
PCT/EP2005/056793 WO2006064026A1 (en) 2004-12-16 2005-12-14 Treatment of hepatitis c in the asian population with interferon-beta

Publications (1)

Publication Number Publication Date
NO20073632L true NO20073632L (no) 2007-09-17

Family

ID=34930073

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073632A NO20073632L (no) 2004-12-16 2007-07-13 Behandling av hepatitt C med interferon-beta i en asiatisk populasjon

Country Status (12)

Country Link
US (1) US20080075696A1 (ja)
EP (1) EP1824507A1 (ja)
JP (1) JP2008524160A (ja)
KR (1) KR20070090002A (ja)
CN (1) CN101123979A (ja)
AR (1) AR052165A1 (ja)
AU (1) AU2005315618A1 (ja)
CA (1) CA2589498A1 (ja)
IL (1) IL183929A0 (ja)
NO (1) NO20073632L (ja)
TW (1) TW200633718A (ja)
WO (1) WO2006064026A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CN102333772B (zh) * 2009-06-11 2013-12-11 雅培制药有限公司 抗病毒化合物
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
DE3273787D1 (en) * 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) * 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4695195A (en) * 1986-03-05 1987-09-22 Brande Bruce R Folding boat dock
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE68926888T2 (de) * 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
ES2224649T3 (es) * 1998-04-28 2005-03-01 Applied Research Systems Ars Holding N.V. Conjugados de poliol-ifn-beta.
JP2000007578A (ja) * 1998-06-24 2000-01-11 Hiroaki Okushin Ｃ型肝炎ウイルスの陰性化のための投薬システム
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
TWI334785B (en) * 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
CA2497777A1 (en) * 2002-09-05 2004-03-18 The General Hospital Corporation Modified asialo-interferons and uses thereof
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta

Also Published As

Publication number Publication date
AR052165A1 (es) 2007-03-07
WO2006064026A1 (en) 2006-06-22
US20080075696A1 (en) 2008-03-27
KR20070090002A (ko) 2007-09-04
JP2008524160A (ja) 2008-07-10
CA2589498A1 (en) 2006-06-22
CN101123979A (zh) 2008-02-13
EP1824507A1 (en) 2007-08-29
AU2005315618A1 (en) 2006-06-22
IL183929A0 (en) 2008-12-29
TW200633718A (en) 2006-10-01

Similar Documents

Publication Publication Date Title
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
DK1658302T3 (da) Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
TW200633995A (en) Andrographolide derivatives to treat viral infections
AP2006003542A0 (en) Administration of TLR7 ligands and prodrugs for treatment of infection by hepatitis C virus.
DE60215157D1 (de) Verwendungen von antiviralen nucleosid-derivaten zur herstellung eines medikaments zur behandlung von hepatitis c infektionen
NO20062428L (no) Kombinasjoner for HCV-behandling
MA32634B1 (fr) Polytherapie destinee a traiter une infection par le vhc
BRPI0410456B8 (pt) compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
BR112012022311A2 (pt) agentes farmacêuticos de combinação como inibidores da replicação de hcv.
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
BR122020006906B8 (pt) compostos e composições farmacêuticas antivirais
NO20052310L (no) Posisjonsisomerer av PEG IFN alfa 2A.
ATE525070T1 (de) Silbininkomponente zur behandlung von hepatitis
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
NO20034878D0 (no) Antivirale forbindelser
EP1765330A4 (en) PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS
EA201170484A1 (ru) Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
IL203873A0 (en) Novel targets and compounds for therapeutic intervention of hiv infection
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
MXPA05008507A (es) Medicamento para enfermedad viral.
RS105104A (en) Treatment of hepatitis c in asian population with subcutaneous interferonbeta
NO20080495L (no) PEG-IFN-alfa og ribavirin for HBV-behandling
EA200700878A1 (ru) Лечение или предупреждение геморрагических вирусных инфекций с помощью иммуномодулирующих соединений

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application